Yuanting Gu

1.1k total citations
19 papers, 394 citations indexed

About

Yuanting Gu is a scholar working on Cancer Research, Molecular Biology and Oncology. According to data from OpenAlex, Yuanting Gu has authored 19 papers receiving a total of 394 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Cancer Research, 12 papers in Molecular Biology and 4 papers in Oncology. Recurrent topics in Yuanting Gu's work include Cancer-related molecular mechanisms research (9 papers), MicroRNA in disease regulation (8 papers) and Circular RNAs in diseases (7 papers). Yuanting Gu is often cited by papers focused on Cancer-related molecular mechanisms research (9 papers), MicroRNA in disease regulation (8 papers) and Circular RNAs in diseases (7 papers). Yuanting Gu collaborates with scholars based in China, Russia and India. Yuanting Gu's co-authors include Guangcheng Guo, Xin Ge, Mingzhi Zhu, Pengwei Lv, Youyi Xiong, Xinguang Qiu, Fang Wang, Yimeng Wang, Mingli Han and Xue Yang and has published in prestigious journals such as Journal of Clinical Oncology, Biochemical and Biophysical Research Communications and European Journal of Pharmacology.

In The Last Decade

Yuanting Gu

17 papers receiving 389 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Yuanting Gu China 12 322 292 56 27 27 19 394
Jens Claus Hahne United Kingdom 4 270 0.8× 255 0.9× 34 0.6× 20 0.7× 25 0.9× 5 384
Yugang Ge China 11 256 0.8× 207 0.7× 53 0.9× 34 1.3× 44 1.6× 17 330
Yusaku Osako Japan 9 309 1.0× 266 0.9× 89 1.6× 37 1.4× 44 1.6× 13 400
Zehui Hou China 11 265 0.8× 223 0.8× 55 1.0× 22 0.8× 34 1.3× 20 341
Changshui Zhuang China 11 358 1.1× 215 0.7× 34 0.6× 23 0.9× 39 1.4× 12 396
Zhendong Xiang China 13 302 0.9× 265 0.9× 29 0.5× 26 1.0× 76 2.8× 15 395
Shuyu Zhai China 9 241 0.7× 213 0.7× 86 1.5× 40 1.5× 37 1.4× 21 345
HUIXING PAN China 11 230 0.7× 206 0.7× 32 0.6× 25 0.9× 29 1.1× 15 286
Mehmet Buğrahan Düz Türkiye 8 190 0.6× 144 0.5× 71 1.3× 27 1.0× 39 1.4× 17 288
Haojie Dong China 10 220 0.7× 150 0.5× 26 0.5× 16 0.6× 23 0.9× 22 305

Countries citing papers authored by Yuanting Gu

Since Specialization
Citations

This map shows the geographic impact of Yuanting Gu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yuanting Gu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yuanting Gu more than expected).

Fields of papers citing papers by Yuanting Gu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yuanting Gu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yuanting Gu. The network helps show where Yuanting Gu may publish in the future.

Co-authorship network of co-authors of Yuanting Gu

This figure shows the co-authorship network connecting the top 25 collaborators of Yuanting Gu. A scholar is included among the top collaborators of Yuanting Gu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yuanting Gu. Yuanting Gu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
2.
Liu, Lu, Mingzhi Zhu, Yanyan Wang, Muhan Li, & Yuanting Gu. (2023). Neoadjuvant pyrotinib plus trastuzumab and chemotherapy for HER2-positive breast cancer: a prospective cohort study. World Journal of Surgical Oncology. 21(1). 389–389. 4 indexed citations
3.
Chen, Kuo, Narasimha M. Beeraka, Mikhail Y. Sinelnikov, et al.. (2022). Patient Management Strategies in Perioperative, Intraoperative, and Postoperative Period in Breast Reconstruction With DIEP-Flap: Clinical Recommendations. Frontiers in Surgery. 9. 729181–729181. 16 indexed citations
4.
Chen, Kuo, Narasimha M. Beeraka, Yuanting Gu, et al.. (2021). Totally Implantable Venous Access Port Systems: Implant Depth-based Complications in Breast Cancer Therapy - A Comparative Study. Current Pharmaceutical Design. 27(46). 4671–4676. 7 indexed citations
5.
Wang, Yanyan, Kang Cui, Mingzhi Zhu, & Yuanting Gu. (2020). Coexpression Module Construction by Weighted Gene Coexpression Network Analysis and Identify Potential Prognostic Markers of Breast Cancer. Cancer Biotherapy and Radiopharmaceuticals. 37(8). 612–623. 3 indexed citations
6.
7.
Wang, Nan, Lin Li, Fang Wang, et al.. (2019). <p>Long Non-Coding RNA HULC Promotes the Development of Breast Cancer Through Regulating LYPD1 Expression by Sponging miR-6754-5p</p>. OncoTargets and Therapy. Volume 12. 10671–10679. 22 indexed citations
8.
Xiong, Youyi, Yuanting Gu, Fang Wang, et al.. (2019). LINC01857 as an oncogene regulates CREB1 activation by interacting with CREBBP in breast cancer. Journal of Cellular Physiology. 234(8). 14031–14039. 24 indexed citations
9.
Han, Mingli, Yimeng Wang, Yuanting Gu, et al.. (2019). lncRNA GHET1 knockdown suppresses breast cancer activity in vitro and in vivo.. PubMed. 11(1). 31–44. 11 indexed citations
10.
Lv, Pengwei, Xinguang Qiu, Yuanting Gu, et al.. (2018). Long non-coding RNA SNHG6 enhances cell proliferation, migration and invasion by regulating miR-26a-5p/MAPK6 in breast cancer. Biomedicine & Pharmacotherapy. 110. 294–301. 62 indexed citations
11.
Wang, Xiaochun, Fang Wang, Lin Li, et al.. (2018). miR-381 induces sensitivity of breast cancer cells to doxorubicin by inactivation of MAPK signaling via FYN. European Journal of Pharmacology. 839. 66–75. 25 indexed citations
12.
Wang, Fang, Pengwei Lv, Yuanting Gu, et al.. (2017). Galectin-1 knockdown improves drug sensitivity of breast cancer by reducing P-glycoprotein expression through inhibiting the Raf-1/AP-1 signaling pathway. Oncotarget. 8(15). 25097–25106. 20 indexed citations
13.
Gu, Yuanting, Shuguang Zhu, Han Du, et al.. (2016). The clinical application of magnetically guided capsule endoscopy to 500 cases of gastric examination. Zhonghua xiaohua neijing zazhi. 33(11). 778–783.
14.
Han, Mingli, Fang Wang, Yuanting Gu, et al.. (2016). MicroR-760 suppresses cancer stem cell subpopulation and breast cancer cell proliferation and metastasis: By down-regulating NANOG. Biomedicine & Pharmacotherapy. 80. 304–310. 39 indexed citations
15.
Zhang, Jianxiang, Yanmei Ma, Shoujun Wang, Fu Chen, & Yuanting Gu. (2016). Suppression of SOX18 by siRNA inhibits cell growth and invasion of breast cancer cells. Oncology Reports. 35(6). 3721–3727. 25 indexed citations
16.
Lu, Pengwei, Yuanting Gu, Lin Li, Fang Wang, & Xinguang Qiu. (2016). miR-544a Promotes Breast Cancer Cell Migration and Invasion Reducing Cadherin 1 Expression. Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics. 23(4). 165–170. 6 indexed citations
17.
Ge, Xin, et al.. (2015). Overexpression of miR-206 suppresses glycolysis, proliferation and migration in breast cancer cells via PFKFB3 targeting. Biochemical and Biophysical Research Communications. 463(4). 1115–1121. 71 indexed citations
18.
Han, Mingli, Fang Wang, Yuanting Gu, et al.. (2015). MicroRNA-21 induces breast cancer cell invasion and migration by suppressing smad7 via EGF and TGF-β pathways. Oncology Reports. 35(1). 73–80. 44 indexed citations
19.
Zhang, Jianxiang, Yanmei Ma, Shoujun Wang, Fu Chen, & Yuanting Gu. (2015). C/EBPα inhibits proliferation of breast cancer cells via a novel pathway of miR-134/CREB.. PubMed. 8(11). 14472–8. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jens Claus Hahne Breakdown of academic impact, for papers by Yugang Ge Breakdown of academic impact, for papers by Yusaku Osako Breakdown of academic impact, for papers by Zehui Hou Breakdown of academic impact, for papers by Changshui Zhuang Breakdown of academic impact, for papers by Zhendong Xiang Breakdown of academic impact, for papers by Shuyu Zhai Breakdown of academic impact, for papers by HUIXING PAN Breakdown of academic impact, for papers by Mehmet Buğrahan Düz Breakdown of academic impact, for papers by Haojie Dong
Rankless by CCL
2026